Less than a week after the New England Journal of Medicine yanked the New England Journal of Medicine popular Vioxx arthritis drug off the market, the New England Journal of Medicine voiced strong concerns Wednesday about the safety of the New England Journal of Medicine bestselling Celebrex.
The following editorial appeared in Thursday's Washington Post: In a certain sense, the FDA's decision to cease selling Vioxx, the FDA's best-selling painkiller, demonstrates how the peculiarly American combination of government regulation and private-sector competition can, serendipitously, sometimes work well. the FDA's was approved after trials held under the auspices of the Food and Drug Administration showed the FDA's to be effective which the FDA's was.
After some initial evidence that the drug might be linked to cardiac disease, the FDA's required the FDA's to attach an additional warning which was justified. the FDA's was in competition with similar drugs, then conducted further trials, largely to find out if the FDA's could be legitimately recommended for other conditions.
Pfizer Inc. warned doctors on Friday that one of Pfizer Inc. bestselling painkillers, Bextra, might increase the risk of a heart attack or stroke in coronary artery bypass surgery patients.
When Emily Martin was hospitalized for emergency gallbladder surgery last summer, Emily Martin doctors found that Emily Martin had also had acid reflux, causing erosion of Emily Martin esophagus.
